NASDAQ · TVRD
Tvardi Therapeutics, Inc.
$0.86-$0.02 (-2.73%)
Tvardi Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.83% below the high.
Loading market information…
NASDAQ · NLTX · USD
Stock price, earnings
Quote as of Dec 18, 2023, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Neoleukin Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.44% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Neoleukin Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical enterprise focused on developing immune-based treatments for conditions such as cancer, inflammatory responses, and autoimmune diseases, utilizing its proprietary protein design technology. The company's leading investigational therapy is NL-201, a novel protein meticulously crafted to emulate the therapeutic effects of the IL-2/IL-15 cytokines. This product candidate is intended for the management of various malignancies, including renal cell carcinoma and melanoma. The organization, founded in 2003, was previously known as Aquinox Pharmaceuticals, Inc. before officially changing its name to Neoleukin Therapeutics, Inc. in August 2019. Its operations are based out of Seattle, Washington.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:17 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2021 |
|---|
| Mar 1, 2022 |
| -$1.40+6.67% vs estimate |
| $6.00K |
THE ANALYST VIEW
14 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.86-$0.02 (-2.73%)
Tvardi Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.83% below the high.
$0.33+$0.33 (+100.0%)
Centogene N.V.’s quoted price sits in the lower half of its reported 52-week range, 24.24% below the high.
$1.35+$0.09 (+7.14%)
Channel Therapeutics Corporation’s quoted price sits in the lower half of its reported 52-week range, 97.51% below the high.
$0.36$0.00 (0.0%)
Turnstone Biologics Corp.’s quoted price sits in the lower half of its reported 52-week range, 84.3% below the high.
$0.47$0.00 (0.0%)
ProSomnus, Inc.’s quoted price sits in the lower half of its reported 52-week range, 6.0% below the high.
$0.14$0.00 (0.0%)
Omega Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 96.79% below the high.
$0.69$0.00 (0.0%)
Lannett Company, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.57% below the high.
CA$9.00+CA$0.20 (+2.27%)
COSCIENS Biopharma Inc.’s quoted price sits in the lower half of its reported 52-week range, 77.27% below the high.
